Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Stem Cell Research

  Free Subscription


Articles published in Leuk Res

Retrieve available abstracts of 34 articles:
HTML format
Text format



Single Articles


    March 2017
  1. GONZALEZ-VICENT M, Molina B, Deltoro N, Sevilla J, et al
    Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors.
    Leuk Res. 2017;57:60-64.
    PubMed     Text format     Abstract available


    February 2017
  2. GAO L, Liu J, Zhang Y, Chen X, et al
    Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation.
    Leuk Res. 2017;57:27-36.
    PubMed     Text format     Abstract available


  3. ZHAO P, Chen Y, Yue Z, Yuan Y, et al
    Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway.
    Leuk Res. 2017;57:20-26.
    PubMed     Text format     Abstract available


    January 2017
  4. YAO J, Zhang G, Liang C, Li G, et al
    Combination of cytogenetic classification and MRD status correlates with outcome of autologous versus allogeneic stem cell transplantation in adults with primary acute myeloid leukemia in first remission.
    Leuk Res. 2017;55:97-104.
    PubMed     Text format     Abstract available


  5. DING L, Zhu H, Yang Y, Yan HM, et al
    The absolute number of regulatory T cells in unmanipulated peripheral blood grafts predicts the occurrence of acute graft-versus-host disease post haplo-identical hematopoietic stem cell transplantation.
    Leuk Res. 2017;56:13-20.
    PubMed     Text format     Abstract available


  6. DROKOV MY, Davydova JO, Kuzmina LA, Galtseva IV, et al
    Level of Granzyme B-positive T-regulatory cells is a strong predictor biomarker of acute Graft-versus-host disease after day +30 after allo-HSCT.
    Leuk Res. 2017;54:25-29.
    PubMed     Text format     Abstract available


  7. WANG L, Raffoux E, Thomas X, Yakoub-Agha I, et al
    Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.
    Leuk Res. 2017;54:12-16.
    PubMed     Text format     Abstract available


    December 2016
  8. LAZZAROTTO D, Candoni A, Fili C, Forghieri F, et al
    Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey.
    Leuk Res. 2016;53:74-81.
    PubMed     Text format     Abstract available


  9. HEINI AD, Berger MD, Seipel K, Taleghani BM, et al
    Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.
    Leuk Res. 2016;53:28-34.
    PubMed     Text format     Abstract available


    July 2016
  10. GHOBADI A, Choi J, Fiala MA, Fletcher T, et al
    Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
    Leuk Res. 2016;49:1-6.
    PubMed     Text format     Abstract available


    June 2016
  11. LUO Y, Zeng HQ, Shen Y, Zhang P, et al
    Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
    Leuk Res. 2016;48:6-10.
    PubMed     Text format     Abstract available


  12. SAITO B, Hattori N, Yamamoto K, Arai N, et al
    Umbilical cord blood transplantation for adults using tacrolimus with two-day very-short-term methotrexate for graft-versus-host disease prophylaxis.
    Leuk Res. 2016;47:161-165.
    PubMed     Text format     Abstract available


    May 2016
  13. TOMASIUK R, Gawronski K, Rzepecki P, Rabijewski M, et al
    The evaluation of NT-proCNP, C-reactive protein and serum amyloid A protein concentration in patients with multiple myeloma undergoing stem cell transplantation.
    Leuk Res. 2016;47:123-127.
    PubMed     Text format     Abstract available


  14. WANG J, Hu J, Jin Z, Wan H, et al
    The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Leuk Res. 2016;47:32-40.
    PubMed     Text format     Abstract available


  15. MEDINGER M, Heim D, Gerull S, Halter J, et al
    Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Leuk Res. 2016;47:22-25.
    PubMed     Text format     Abstract available


    April 2016
  16. FANG J, Zhang R, Wang H, Hong M, et al
    Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.
    Leuk Res. 2016;46:61-68.
    PubMed     Text format     Abstract available


  17. VON DEM BORNE PA, de Wreede LC, Halkes CJ, Marijt WA, et al
    Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy.
    Leuk Res. 2016;46:45-50.
    PubMed     Text format     Abstract available


  18. TIAN H, Xu Y, Liu L, Yan L, et al
    Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone.
    Leuk Res. 2016;45:40-46.
    PubMed     Text format     Abstract available


  19. KOUVIDI E, Stratigi A, Batsali A, Mavroudi I, et al
    Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion.
    Leuk Res. 2016;43:24-32.
    PubMed     Text format     Abstract available


    March 2016
  20. HO H, Skaist AM, Pallavajjala A, Yonescu R, et al
    NUP98-PHF23 fusion is recurrent in acute myeloid leukemia and shares gene expression signature of leukemic stem cells.
    Leuk Res. 2016;45:1-7.
    PubMed     Text format     Abstract available


  21. CARRETT-DIAS M, Almeida LK, Pereira JL, Almeida DV, et al
    Cell differentiation and the multiple drug resistance phenotype in human erythroleukemic cells.
    Leuk Res. 2016;42:13-20.
    PubMed     Text format     Abstract available


    January 2016
  22. MINETTO P, Guolo F, Miglino M
    Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia.
    Leuk Res. 2016 Jan 22. pii: S0145-2126(16)30005.
    PubMed     Text format    


  23. NISCOLA P, Cupelli L, Dentamaro T, Fabritiis P, et al
    Chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia: a way to improve the outcome?
    Leuk Res. 2016 Jan 4. pii: S0145-2126(15)30571.
    PubMed     Text format    


  24. NOROZI F, Shahrabi S, Mendelson A, Hajizamani S, et al
    Regulatory role of Megakaryocytes on Hematopoietic Stem Cells Quiescence by CXCL4/PF4 in Bone Marrow Niche.
    Leuk Res. 2016 Jan 2. pii: S0145-2126(15)30569.
    PubMed     Text format     Abstract available


  25. TEOH HK, Chong PP, Abdullah M, Sekawi Z, et al
    Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth.
    Leuk Res. 2016;40:44-53.
    PubMed     Text format     Abstract available


    December 2015
  26. ITONAGA H, Iwanaga M, Aoki K, Aoki J, et al
    Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
    Leuk Res. 2015 Dec 24. pii: S0145-2126(15)30561.
    PubMed     Text format     Abstract available


  27. GHASEMZADEH M, Hosseini E, Schwarer AP, Pourfathollah AA, et al
    NK cell maturation to CD56 subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2015 Dec 17. pii: S0145-2126(15)30559.
    PubMed     Text format     Abstract available


  28. BERMAN E, Maloy M, Devlin S, Jhanwar S, et al
    Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation.
    Leuk Res. 2015 Dec 2. pii: S0145-2126(15)30549.
    PubMed     Text format     Abstract available


  29. DAMDINSUREN A, Matsushita H, Ito M, Tanaka M, et al
    FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
    Leuk Res. 2015;39:1405-13.
    PubMed     Text format     Abstract available


    October 2015
  30. LIU N, Ning HM, Hu LD, Jiang M, et al
    Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
    Leuk Res. 2015 Oct 19. pii: S0145-2126(15)30533.
    PubMed     Text format     Abstract available


  31. COGLE CR, Saki N, Khodadi E, Li J, et al
    Bone marrow niche in the myelodysplastic syndromes.
    Leuk Res. 2015;39:1020-7.
    PubMed     Text format     Abstract available


  32. WANG WZ, Pu QH, Lin XH, Liu MY, et al
    Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
    Leuk Res. 2015;39:1117-24.
    PubMed     Text format     Abstract available


  33. UY GL, Hsu YS, Schmidt AP, Stock W, et al
    Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
    Leuk Res. 2015 Oct 1. pii: S0145-2126(15)30391.
    PubMed     Text format     Abstract available


    September 2015
  34. WANG F, Liu Z, Zeng J, Zhu H, et al
    Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
    Leuk Res. 2015 Sep 18. pii: S0145-2126(15)30387.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: